Gabapentin attenuates superior oblique myokymia.
OBJECTIVE
To investigate therapeutic effects of oral gabapentin therapy on superior oblique myokymia.


METHODS
Observational case series with measurement of visual acuity and eye movements before, during, and after therapy.


METHODS
Two adult patients with superior oblique myokymia, refractory to other therapies, were treated with gabapentin orally after informed consent was obtained. Eye movements were measured using the magnetic search coil technique.


RESULTS
Superior oblique myokymia completely resolved after starting gabapentin.


CONCLUSIONS
Gabapentin may be an effective treatment for superior oblique myokymia; a double-blind study seems justified.
Tomsak
Robert L
RL
Department of Neurology, Case Western Reserve University, Cleveland, Ohio, USA. robert.tomsak@uhhs.com
Kosmorsky
Gregory S
GS
Leigh
R John
RJ
D000085:Acetates / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D004172:Diplopia / Q000188:drug therapy* / Q000209:etiology; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005133:Eye Movements; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D020432:Trochlear Nerve Diseases / Q000150:complications / Q000188:drug therapy*; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin